Drug intelligence / Profile preview

Renshu Changle

Development stage
Phase 3
Lead developer
Hong Kong Baptist University
Administration
Oral
01

Overview

Renshu Changle (RSCL) is a Chinese herbal formula developed by Hong Kong Baptist University (HKBU) specifically for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). It represents a significant milestone as the first traditional Chinese medicine (TCM) developed by a Hong Kong institution to receive clinical trial approval from the National Medical Products Administration (NMPA) of China. The formula is designed to address the TCM pattern of "spleen deficiency and liver stagnation," which manifests as abdominal pain, stool urgency, and frequent bowel movements. Mechanistically, RSCL is thought to modulate the brain-gut axis, regulate serotonin (5-HT) signaling in the intestinal mucosa, and improve gut microbiota diversity, thereby reducing visceral hypersensitivity and restoring intestinal barrier function.

Brand names
Renshu Changle
Other names
Renshu Changle GranulesRSCL formula
02

Targets

AKT (RAC-alpha serine/threonine-protein kinase)HSP90AA1 (Heat shock protein HSP90-alpha)NOS3 (eNOS)HTR3A (5-hydroxytryptamine receptor 3A)HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on Renshu Changle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renshu Changle.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call